On screen, everything works. The report appears, the alert comes through, and the patient journey finally looks seamless. Then Monday morning arrives on a hospital ward: a failed login, a mismatched patient identity, a nurse already overwhelmed. For a healthcare startup, this is where the real product begins. Looking ahead to September 2026, the decisive question is no longer simply whether a technology can help. It is whether it can become part of care without disrupting the people who deliver it.
The demo convinces; deployment demands commitment
A demo controls its environment: selected data, prepared users, an uninterrupted scenario. Real-world conditions impose the opposite. Information arrives incomplete, several professionals are involved, and systems do not always speak the same language. A solution can pass its technical test while adding a task that no one has time to perform.
Remote patient monitoring illustrates this difference. Collecting a measurement at home is just one step. Decisions are needed on who reviews alerts, how quickly, who provides cover during absences, and what is recorded in the patient record. Its inclusion in France’s standard reimbursement framework in 2023 marked an important shift: behind the connected device lies an organised medical activity that must be funded and made to work.
The first deployment is therefore as much an entrepreneurial test as a clinical one. It reveals installation costs, the support burden, the adaptations required and dependence on a handful of motivated people. In other words, it tests what the sales presentation generally leaves out: the ability to replicate the service without reinventing the business for every client.
Interoperability is measured by the work it eliminates
In a healthcare facility, an additional application can become yet another window. If clinicians have to search for the patient, copy their medical history and then transfer the result manually, the promised benefit erodes. Interoperability is not a technical bonus: it is often a prerequisite for the solution to be used at all.
Standards such as HL7 FHIR facilitate structured data exchange. DICOM remains central to imaging. But claiming to support them is not enough. Two software systems can use the same standard without sharing the same fields, coding rules or versions. Access rights, duplicate records and silent errors, which are more dangerous than a visible outage, must also be managed.
In France, the Ségur digital health programme, the national health identifier and the services associated with Mon espace santé have reinforced the importance of this shared environment. For an entrepreneur, the lesson is simple: start with the specifications and interfaces actually available at the client’s facility, rather than designing an ideal workflow and then asking the facility to adapt to it.
Choose a narrow but complete scope
A first project benefits from addressing a single use case from end to end: a defined population, one department, one validation workflow. A result properly integrated into the patient record is better than a platform covering ten disconnected functions. The contract must specify who builds the connector, who maintains it and what happens when the operational software changes.
Sensitive data leaves no room for improvisation
Data protection begins before collection. What information is essential? For what purpose? For how long? Who can access it? These questions shape the product’s architecture. Postponing them until the contract is signed risks discovering that a prototype relies on data uses incompatible with its actual operation.
The GDPR requires, among other things, clarity on roles and the legal bases for processing. Consent is not a universal answer to every operation carried out in the course of care. A data protection impact assessment may be required, particularly for certain types of large-scale health data processing. Entrepreneurs must work with the data protection officer, rather than hand over a dossier set in stone.
In France, an HDS-certified hosting provider must be used in the situations specified by the applicable health data hosting framework. This certification alone does not make the entire application compliant or secure. Authentication, logging, backups, access management and incident response still need to be organised. Any international transfers also require a specific assessment.
AI adds a practical question: is the data used solely to deliver the requested service, or also to improve a model? These purposes must be distinguished, and data processors must be subject to appropriate controls. The European Union’s AI Act, adopted in 2024, provides for phased implementation. Depending on the product’s use and classification, its requirements may apply alongside those governing medical devices: the regulatory timetable must be factored into the development plan.
The real buyer is an organisation
An enthusiastic doctor opens the door, but does not necessarily control the budget, IT access or the authority to change procedures. IT management, procurement, care teams, security officers and finance management each see a different risk. Involving them early helps prevent a well-received trial from leading nowhere.
Above all, the new work must be clearly identified. Who trains temporary staff? Who helps a patient struggling with the interface? Who checks an algorithmic suggestion? A promise of time savings can conceal a shift in workload to another profession. Evaluation must therefore examine the entire care pathway, not just the minutes saved by the primary user.
An outage scenario is part of the product. When the service becomes unavailable, the team must know how to continue providing care and retrieve the information it needs. The ability to switch to a fallback procedure, without data loss or ambiguity over responsibility, is more reassuring than an abstract promise of constant availability.
Turning the pilot into a purchasing decision
Before launching the trial, the partners should define how it will conclude. What result will justify expansion? Who will decide? What budget will take over? Without these answers, the pilot risks becoming an extended demo funded from the startup’s cash reserves.
A few well-chosen indicators are worth more than an impressive dashboard:
- Actual use by the professionals concerned, beyond the initial volunteers.
- Total time spent on the care pathway, including corrections and support.
- Incidents, unnecessary alerts and any consequences for safety.
- The full cost of deployment and ongoing maintenance.
These measures do not replace a clinical evaluation where one is necessary. They show whether the benefit can hold up under everyday conditions. For the company, they also make it possible to calculate a realistic margin that accounts for connectors, training and support, rather than simply the cost of a software subscription.
What next? Looking ahead to September 2026, the advantage could go to startups able to sell less magic and more continuity. The premise is simple: as digital tools proliferate, healthcare facilities should favour those that integrate with existing systems, document their risks and genuinely reduce workloads. The first deployment will then no longer be the final slide in a funding pitch. It will become the central proof point.